Growth Opportunities in the Global Liquid Biopsy Market, 2018

Growth Opportunities in the Global Liquid Biopsy Market, 2018

Liquid biopsy (CTCs and ctDNAs) is slowly gaining momentum in clinical care given its advantages over the traditional tissue-based gold standard methods. Short-term applications in cancer care range from risk assessment to cancer recurrence monitoring. Despite the proven advantages, there is still a significant number of barriers to adoption such as high cost of next-generation sequencing (NGS), reimbursement scenario and the establishment of clinical utility of mutation and clinical evidence.

Liquid biopsy remains an interesting business opportunity for several investors and the quest for the most successful company continues. With GRAIL announcing over $1.3 billion in financing, the modality has also garnered interest from several pharma companies vying to capture their share of the market by co-developing drugs and diagnostic products. CTCs and ctDNAs have extended applications across oncology, NIPT (non-invasive prenatal testing), transplant diagnostics and infectious diseases. This report provides a strategic insight into liquid biopsy test makers relating to the challenges they will encounter and lists some of the winning strategies to gain reimbursement and market access. It also highlights growth opportunities where companies can gain the first-mover advantage, and provides a guidance for investment bankers on the most successful and unique disruptive technology.

It is important to identify winning strategies in order to be successful. Given the tricky nature of this market, establishing clinical utility and clinical evidence and getting the test into guidelines are some of the key pathways for success. This report discusses regional challenges, regulatory barriers in the UK, China and the US. Key drivers would include the following: Identifying the area of unmet need; aiming for incorporating the test within guidelines and screening programs; overcoming regulatory and reimbursement barriers; and innovating to draw maximum capital from investors.

Broadly three types of companies form the competitive landscape in this market - liquid biopsy kit providers, liquid biopsy instrument providers. Most activity is sensed within “liquid biopsy as a service model”.

Currently, there are no clear guidelines that provide a definitive regulatory/ reimbursement roadmap in emerging countries such as India where the concept is still in its nascent stages.

Top market trends include:
• Increasing interest from pharma companies forging partnerships with diagnostic test developers to advance their drug discovery and development activities.
• Companies are leaning towards biomarkers that are listed in the NCCN guidelines as a low-risk approach and which offer more guaranteed reimbursement.
• Biomarker tests are focusing on multi-gene or multi-cancer testing rather than a single gene approach.
• Companies are pushing the boundaries beyond oncology testing.

  • Executive Dashboard
    • Purpose of this Experiential Study
    • 5 Step Process to Transformational Growth
    • Scope and Segmentation
    • Market Highlights
    • Strategic Imperatives for Suppliers and Laboratories
    • Growth Themes for the Liquid Biopsy Market
    • Key Questions this Study will Answer
    • Top 3 Predictions
  • Market Overview
    • What is Liquid Biopsy?
    • Overview of Liquid Biopsy Techniques and Biomarkers
    • Liquid Biopsy—Where are the Growth Opportunities?
    • Tapping into Oncology-specific Opportunities
    • Deeper Look Into Biopsies
      • Table Liquid Biopsy Market: Number of Biopsies, US, 2017-2021
    • Key Stakeholders (Full Adoption of Liquid Biopsy)
    • Clinical Trials in Liquid Biopsy
    • Market Landscape—Pharmaceutical Investments
    • Market Drivers
    • Market Restraints
    • Commercialized Tests (US)
    • Impact of NCD on Liquid Biopsy Testing
    • Notable Market Activities
    • Market Landscape—Investments
  • Competitor Landscape
    • Overall Competitive Landscape—Types of Companies
    • Overview of Competitive Landscape—Service Providers
    • Top 3 Trends and Vendor Strategies
    • Key Focus Areas of Liquid Biopsy Companies
    • Liquid Biopsy Service Provider—Competitor Analysis Snapshot
    • Investments and Technology—By Company
    • Investments—By Technology
    • Biomarker and Technology Choice Analysis
    • Competitor Matrix—Product Type
  • Regional Analysis
    • Predictions on Adoption of Liquid Biopsy Across Geographies
    • Analysis—US
    • Analysis—Europe/UK
    • Analysis—China
    • Analysis—India
  • Growth Strategy
    • Growth Opportunities
    • Growth Opportunity 1—Tool to Predict Response to Therapy
    • Growth Opportunity 2—Prognosis and Early Detection for Cancer
    • Growth Opportunity 3—Moving Beyond Routine Cancers
    • Growth Opportunity 4—Technology Advancements
    • 2018 Liquid Biopsy Market Participant Strategies
    • Winning Strategies—Recommended Growth Strategies
    • Importance of Clinical Validation and Clinical Utility and Path to Reimbursement
    • GRAIL—Strong Clinical Trial Strategy and Technology Superiority Using AI/ML
    • Guardant Health—Established Presence in Recurrence Monitoring
    • Freenome—Early-stage Company Focusing on Machine Learning Technology
    • Biocept
    • Natera—Building on the NIPT Expertise
    • Companies to Action (C2A Summary)
    • Path to Reimbursement/Coverage
  • The Last Word
    • Key Conclusions and Future Outlook
    • Acronyms
  • Appendix (Capital Pricing and Installed Base)
    • List of Companies Mentioned in the Report

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook